{"TopicDetails": {"type": 0, "ccm2Id": 44835237, "cftId": 0, "identifier": "EU4H-2022-PJ-04", "title": "Call for proposals to support the implementation of the Regulation on health technology assessment \u2013 training of patient and clinical experts contributing to joint health technology assessment activities", "publicationDateLong": 1644883200000, "callIdentifier": "EU4H-2022-PJ", "callTitle": "Action Grants 2022 - first wave", "callccm2Id": 44774006, "allowPartnerSearch": true, "workProgrammepart": {"id": 6515, "ccm_id": 45114455, "wp_part": "EU4H-2022", "wp_year": "EU4H-2022", "wp_title": "EU4H-2022"}, "frameworkProgramme": {"id": 43332642, "abbreviation": "EU4H", "description": "EU4 Health Programme (EU4H)"}, "programmeDivision": [{"id": 43332657, "abbreviation": "Health", "description": "Improving and fostering health in the Union to reduce the burden of communicable and non-communicable diseases"}, {"id": 43332653, "abbreviation": "EU4H-1", "description": "EU4H-1"}], "topicMGAs": [], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "EU4H-PJG EU4H Project Grants", "typeOfMGA": [{"id": 43326018, "abbreviation": "EU4H-AG", "description": "EU4H Action Grant Budget-Based"}]}], "plannedOpeningDate": "22 February 2022", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["24 May 2022"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3382182": [{"action": "EU4H-2022-PJ-08 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 300000}, "budgetTopicActionMap": {}}], "3382184": [{"action": "EU4H-2022-PJ-05 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 4000000}, "budgetTopicActionMap": {}}], "3382186": [{"action": "EU4H-2022-PJ-04 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 1000000}, "budgetTopicActionMap": {}}], "3382188": [{"action": "EU4H-2022-PJ-01 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 30000000}, "budgetTopicActionMap": {}}], "3382190": [{"action": "EU4H-2022-PJ-02 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 5000000}, "budgetTopicActionMap": {}}], "3382192": [{"action": "EU4H-2022-PJ-07 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 30000000}, "budgetTopicActionMap": {}}], "3382194": [{"action": "EU4H-2022-PJ-06 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 29000000}, "budgetTopicActionMap": {}}], "3382196": [{"action": "EU4H-2022-PJ-03 - EU4H-PJG EU4H Project Grants", "plannedOpeningDate": "22 February 2022", "deadlineModel": "single-stage", "deadlineDates": ["24 May 2022"], "budgetYearMap": {"2022": 8000000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2022"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p><strong><span><span><span style=\"color:black\">Background and policy context</span></span></span></strong></p><p><span><span><span><span style=\"color:black\">As laid down in the Regulation on health technology assessment (\u2018the HTA Regulation\u2019) patient and clinical experts will play an important role in implementing the new framework. In order to ensure that joint work is of the highest scientific quality and reflects the state of the art, the HTA Regulation establishes that external experts with relevant in-depth specialised expertise should provide input on joint clinical assessments and joint scientific consultations. Such experts should include clinical experts in the therapeutic area concerned, patients affected by the disease, and other relevant experts on, for example, the type of technology concerned or issues related to the relevant clinical study design. In addition, patient organisations and learned societies will have the opportunity to provide input through the Stakeholder Network. </span></span></span></span></p><p><span><span><span><span style=\"color:black\">The EUnetHTA joint actions took the first steps to engage external experts in their activities, however currently there is still further need to engage patients and clinical experts as experts contributing to joint scientific consultations and joint clinical assessments. There is therefore a need to put in place appropriate training programmes for both patient and clinical experts. Such training should be based on the work carried out by EUnetHTA joint actions and the subsequent adaptation to fulfil the needs set out in the HTA Regulation. This action should ensure the appropriate and timely contribution to the joint activities that should start at the implementation date. Transparency on funding as well as representativeness and independence of the experts and organisations involved are key in the appropriate implementation of the action. </span></span></span></span></p><p><span><span><span style=\"color:black\">This action supports the implementation of the HTA Regulation and implements the EU4Health Programme\u2019s general objective of strengthening health systems (Article 3, point (d)) through the specific objectives defined in Article 4, points (h) and (i), of Regulation (EU) 2021/522.</span></span></span></p>\n<SPAN class=\"topicdescriptionkind\">Objective</SPAN>:<p><strong><span><span><span style=\"color:black\">Objectives pursued </span></span></span></strong></p><p><span><span><span style=\"color:black\">The action will support a timely implementation of the new legislation through capacity building activities. It is divided in two subtopics: subtopic a) on patient experts, subtopic b) on clinical experts.</span></span></span></p><p><strong><span><span><span style=\"color:black\">Description of the activities to be funded under this topic</span></span></span></strong></p><p><span><span><span style=\"color:black\">a) Increasing the capacity of patient organisations and learned societies to provide robust and meaningful input to HTA activities carried out by the Coordination Group and its sub-groups, including dissemination of the output produced;</span></span></span></p><p><span><span><span style=\"color:black\">b) Increasing the knowledge of patients and clinical experts on the new Union HTA legal framework, clarifying their role when invited to contribute to joint HTA activities for their subject matter expertise and acting in individual capacity (rather than representing any particular organisation, institution, or Member State);</span></span></span></p><p><span><span><span style=\"color:black\">c) Ensuring the appropriate implementation of the rules to ensure the independence and impartiality of patients and clinical experts involved in joint HTA work.</span></span></span></p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p><strong><span><span><span style=\"color:black\">Expected results and impact</span></span></span></strong></p><p><span><span><span><span style=\"color:black\">The action is expected to: </span></span></span></span></p><p><span><span><span><span style=\"color:black\">a) develop training programmes for patients and clinical experts participating in their individual capacity to joint scientific consultations and joint clinical assessments; </span></span></span></span></p><p><span><span><span><span style=\"color:black\">b) contribute to the appropriate implementation of the rules to ensure the independence and impartiality of patients and clinical experts involved in joint HTA work; </span></span></span></span></p><p><span><span><span style=\"color:black\">c) raise awareness among patient and clinical experts on the new Union legal framework on HTA and stimulate their engagement with HTA bodies at national and Union level, including dissemination of produced output. </span></span></span></p><p><strong><span><span><span style=\"color:black\">Specific mandatory deliverables and/or milestones</span></span></span></strong></p><p><span><span><span style=\"color:black\">For subtopic a)</span></span></span></p><ul level=\"0\"><li><span><span><span>Training programme targeted to patients experts. Training programmes should be developed in English and made available, also online, in as many EU official languages as possible. </span></span></span></li><li><span><span><span>Training sessions. Training sessions could be carried out face to face or online or in combination. If only face to face, the minimum number of training sessions should be 6, if only online, the minimum number of these training sessions should be 10.</span></span></span></li><li><span><span><span>List of national and EU-wide patient organisations per disease area (as a minimum on cancer, including rare cancers) who could support the joint work of Coordination Group in the framework set out by the HTA Regulation. </span></span></span></li><li><span><span><span>List of candidate patient experts trained by the national and/or EU-wide patient organisations who could provide input to joint clinical assessments and joint scientific consultations as set out by the Regulation on HTA (as a minimum in the area of cancer, including rare cancers).</span></span></span></li><li><span><span><span>Dissemination tools (e.g. website, newsletter, leaflet) to increase awareness about the Regulation on HTA among patient organisations.</span></span></span></li> </ul><p><span><span><span style=\"color:black\">For subtopic b)</span></span></span></p><ul level=\"0\"><li><span><span><span>Training programme targeted to clinical experts. Training programmes should be developed in English and made available, also online, in as many EU official languages as possible. </span></span></span></li><li><span><span><span>Training sessions. Training sessions could be carried out face to face or online or in combination. If only face to face, the minimum number of training sessions should be 6 , if only online, the minimum number of these training sessions should be 10.</span></span></span></li><li><span><span><span>List of national and EU-wide organisations such as healthcare professionals, clinical and <em>learned societies</em> per disease area (as a minimum for cancer, including rare cancers) who could support the joint work of Coordination Group as set out in the HTA Regulation. </span></span></span></li><li><span><span><span>List of candidate clinical experts who could provide high-level scientific input to joint HTA work, as set out by the Regulation on HTA, following the training programme (as a minimum in the area of cancer, including rare cancers). </span></span></span></li><li><span><span><span>Dissemination tools (e.g. website, newsletter, leaflet) to increase awareness about the Regulation on HTA among organisations such as healthcare professionals, clinical and learned societies respectively</span></span></span></li> </ul><p><strong><span><span><span style=\"color:black\">Specific action-level indicators for reporting purposes</span></span></span></strong></p><p><span><span><span style=\"color:black\">Applicants must be prepared to include data on the following specific action-level indicators in their regular reporting activities in case of award:</span></span></span></p><p><span><span><span style=\"color:black\">For subtopic a)</span></span></span></p><ul level=\"0\"><li><span><span><span>Number of training sessions developed for patients experts</span></span></span></li><li><span><span><span>Number of participants per training session and programme</span></span></span></li><li><span><span><span>Number of national and EU-wide patient organisations participating to the training programmes developed by this action</span></span></span></li><li><span><span><span>Number of national and EU-wide patient organisations identified per disease area (as a minimum for cancer, including rare cancers)</span></span></span></li><li><span><span><span>Number of candidate patient experts identified and trained per disease area (as a minimum for cancer, including rare cancers)</span></span></span></li><li><span><span><span>Number of dissemination documents (e.g. newsletter, leaflet) produced to increase the awareness of patients about the Regulation on HTA.</span></span></span></li> </ul><p><span><span><span style=\"color:black\">For subtopic b)</span></span></span></p><ul level=\"0\"><li><span><span><span>Number of training sessions developed for clinical experts </span></span></span></li><li><span><span><span>Number of participants per training session and programme</span></span></span></li><li><span><span><span>Number of national and EU-wide healthcare professionals\u2019 organisations and learned societies participating to the training programmes developed by this action</span></span></span></li><li><span><span><span>Number of national and EU-wide healthcare professionals\u2019 organisations and learned societies identified per disease area (as a minimum for cancer, including rare cancers)</span></span></span></li><li><span><span><span>Number of candidate clinical experts per disease area (as a minimum for cancer, including rare cancers)</span></span></span></li><li><span><span><span>Number of dissemination documents (e.g. newsletter, leaflet) produced to increase the awareness of clinical experts about the Regulation on HTA. </span></span></span></li> </ul><p><span><span><span style=\"color:black\">The applicants are required to include in their proposals additional specific action-level indicators which will be agreed with the Commission during the grant agreement preparation. </span></span></span></p><p><span><span><span style=\"color:black\">The Commission may require the awardees to collect data for additional specific action-level indicators, where needed to complement the above indicators.</span></span></span></p>\n", "conditions": "<p><b><span style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\" lang=\"EN-US\">Conditions<br />\r\n</span></b></p>\r\n<p><b><span style=\"color:#404040;mso-themecolor:&#xA;text1;mso-themetint:191;mso-ansi-language:EN-US\" lang=\"EN-US\">1.&nbsp;</span></b><b><span lang=\"EN-US\">Admissibility conditions: </span></b><span lang=\"EN-US\">described in section 5 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">&nbsp;</a></p>\n<p><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\">&nbsp;described in Part B of the Application Form available in the Submission System</span></p>\n<p><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b><span lang=\"EN-US\">described in section 6 of of the<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\"> call document</a></span></p>\n<p><b><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\">&nbsp;described in section 6 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></p>\n<p><b>4. Financial and operational capacity and exclusion:&nbsp;</b>described in&nbsp;<span lang=\"EN-US\">section 7 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></p>\n<p><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></p>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Award criteria, scoring and thresholds:</span></b><span lang=\"EN-US\">&nbsp;described in section 9 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></li>\r\n</ul>\n<ul>\r\n    <li><b><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\">Submission and evaluation processes</span></b><b><span lang=\"EN-US\">:</span></b><span lang=\"EN-US\">&nbsp;described&nbsp;<span style=\"color: rgb(64, 64, 64);\">section 8 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a> and the</span>&nbsp;</span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span lang=\"EN-US\">Online Manual</span></a></li>\r\n</ul>\n<ul>\r\n    <li><b><span lang=\"EN-US\">Indicative timeline for evaluation and grant agreement:&nbsp;</span></b><span lang=\"EN-US\">described in section 4 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></li>\r\n</ul>\n<p><b><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\">6</span></b><b><span lang=\"EN-US\">. Legal and financial set-up of the grants:&nbsp;</span></b><span lang=\"EN-US\">described&nbsp;<span style=\"color: rgb(64, 64, 64);\">in section 10 of the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">call document</a></span></span></p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span style=\"font-size: 12pt; line-height: 18.4px; color: rgb(64, 64, 64);\" lang=\"EN-US\">Documents<br />\r\n<br />\r\n<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#xA;mso-ansi-language:EN-US\" lang=\"EN-US\"><b><span lang=\"EN-US\">Call documents:</span></b></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#xA;mso-ansi-language:EN-US\" lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/wp-call/2022/call-fiche_eu4h-2022-pj_en.pdf\" target=\"_blank\">Call document </a><o:p></o:p></span></p>\r\n<p><strong>EU4health standard application form</strong>:&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/temp-form/af/af_eu4h_en.pdf\" target=\"_blank\">Standard application form</a><br />\r\n<strong>EU4Health detailed budget</strong>:&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/reference-documents;programCode=EU4H\" target=\"_blank\">EU4Health Detailed budget table</a><br />\r\n<strong>EU4Health Programme</strong>:&nbsp;<a href=\"https://ec.europa.eu/health/funding/eu4health_en\" target=\"_blank\">EU4Health programme</a><br />\r\n<strong>EU4Health</strong>:&nbsp;<a href=\"https://ec.europa.eu/health/publications/2022-eu4health-work-programme_en\" target=\"_blank\">2022 Annual Work Programme</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p>&nbsp;</p>\n<p><strong>EU4Health programme:</strong> <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/eu4h/agr-contr/mga_eu4h_en.pdf\" target=\"_blank\">EU4Health&nbsp; MGA v1.0</a><br />\r\n<strong>EU4Health Regulation</strong>:  <a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0522\" target=\"_blank\">Regulation 2021/522</a><br />\r\n<strong>EU financial Regulation</strong>: <a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\" target=\"_blank\">EU Financial Regulation 2018/1046</a></p>\r\n<p>&nbsp;</p>", "supportInfo": "<p><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">For help related to this</span><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">&nbsp;</span><b style=\"font-family: Arial, sans-serif; font-size: 9pt;\">call</b><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\">, please contact:</span><span style=\"font-family: Arial, sans-serif; font-size: 9pt;\"> </span>HaDEA-HP-CALLS@ec.europa.eu </p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;grantAndTendertype=1;categories=p_submission_eval;programme=null;actions=;keyword=;period=null\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Funding &amp; Tenders Portal FAQ</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Submission of proposals.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">IT Helpdesk</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Contact the IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height: normal;\"><a href=\"https://webgate.ec.europa.eu/funding-tenders-opportunities/display/OM/Online+Manual\"><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Online Manual</span></a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; Step-by-step online guide through the Portal processes from proposal preparation and submission to reporting on your on-going project. Valid for all 2021-2027 programmes.</span></p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "", "staticAdditionalInfo": "", "latestInfos": [{"approvalDate": "Oct 26, 2022 11:41:37 AM", "lastChangeDate": "Oct 26, 2022 11:41:37 AM", "content": "<p class=\"MsoNormal\"><span style=\"font-size:10.5pt;line-height:115%;font-family:&#10;&quot;inherit&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&#10;Arial;color:#333333;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;&#10;padding:0cm;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">A total of 41 </span><b><span style=\"font-size:10.5pt;line-height:115%;font-family:&quot;inherit&quot;,serif;&#10;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Helvetica;&#10;color:#333333;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;&#10;padding:0cm;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">proposals have been submitted&nbsp;</span></b><span style=\"font-size:10.5pt;line-height:115%;&#10;font-family:&quot;inherit&quot;,serif;mso-fareast-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-font-family:Arial;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:EN-IE\">in response to this call.</span><span lang=\"EN-GB\"><o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-01: 6 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-02: 5 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-03: 6 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-04: 4 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-05: 1 proposal<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-06: 17 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-07: 1 proposal<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:36.0pt;text-indent:-18.0pt;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"FR\" style=\"font-family:&#10;Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:&#10;FR\"><span style=\"mso-list:Ignore\">&middot;<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"FR\" style=\"mso-ansi-language:FR\">EU4H-2022-PJ-08: 1 proposal<o:p></o:p></span></p>"}, {"approvalDate": "Feb 22, 2022 12:00:08 AM", "lastChangeDate": "Feb 22, 2022 12:00:08 AM", "content": "The submission session is now available for: EU4H-2022-PJ-06(EU4H-PJG), EU4H-2022-PJ-02(EU4H-PJG), EU4H-2022-PJ-03(EU4H-PJG), EU4H-2022-PJ-01(EU4H-PJG), EU4H-2022-PJ-05(EU4H-PJG), EU4H-2022-PJ-08(EU4H-PJG), EU4H-2022-PJ-04(EU4H-PJG), EU4H-2022-PJ-07(EU4H-PJG)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}